CHOLREM

Cholrem is a specialty biopharmaceutical company leveraging advanced proprietary technologies to develop first-in-class treatments. Research into cyclodextrin has quickly proven to emerge as a major therapeutically beneficial product for the 2020 decade. Scientific studies and research into cyclodextrin are showing that enhanced cholesterol transport within the body has major benefits in a huge range of health issues, including Atherosclerosis, Alzheimer's disease, Macular degeneration, and so on. More and more companies are beginning to research end products for cyclodextrin but are years away from having approved products ready for market. Some of these companies are solely dedicated to cyclodextrin research and are valued in excess of $100 million without a single commercial product. While these companies struggle to develop a product for a dedicated treatment, Cholrem has developed its own cyclodextrin (CAVADEX®) and has moved forward and made CAVADEX® available for general use through RemChol®. Cholrem Inc. products provide immediate access to CAVADEX® by the consumer, and as the science shows, CAVADEX® not only avoids harm but also contributes positively to your overall health with each dose you take. Cholrem Inc. is the only company with a commercially available cyclodextrin treatment. Our first product, the RemChol enema, is now available giving consumers immediate access to this incredible compound. The Cholrem Inc. products are designed to deliver up to 8 grams of CAVADEX® daily. This accumulates to over 2,400 grams annually, providing huge health benefits to the consumer. As the science continues to show the benefits of cyclodextrin, Cholrem Inc. is ready to satisfy the increasing demand for this new health-improving treatment.